Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance

Histopathology

Volumn 65, Issue 3, 2014, Pages 328-339

  Lien, Huang Chun ^a   Lee, Yi Hsuan ^b   Jeng, Yung Ming ^a   Lin, Ching Hung ^a   Lu, Yen Shen ^a   Yao, Yu Tung ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Breast; Carcinoma; Epithelial mesenchymal transition; HAS2; Metaplastic carcinoma

Indexed keywords

HYALURONAN SYNTHASE 2; HYALURONIC ACID; SYNTHETASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; GLUCURONOSYLTRANSFERASE; HAS2 PROTEIN, HUMAN; RNA; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM CELL; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CELL CULTURE; COLLOID CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; LUNG CARCINOMA; METABOLISM; METAPLASIA; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; METAPLASIA; PROGNOSIS; RNA, NEOPLASM; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84927568379     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12390     Document Type: Article

References (41)

1. Itano N, Kimata K. Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol. 2008; 18; 268-274.
2. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol. 2006; 85; 699-715.
3. Spicer AP, McDonald JA. Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family. J. Biol. Chem. 1998; 273; 1923-1932.
4. Itano N, Sawai T, Yoshida M et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999; 274; 25085-25092.
5. Brinck J, Heldin P. Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44. Exp. Cell Res. 1999; 252; 342-351.
6. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am. J. Pathol. 1996; 148; 1721-1726.
7. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004; 4; 528-539.
8. Ponting J, Howell A, Pye D, Kumar S. Prognostic relevance of serum hyaluronan levels in patients with breast cancer. Int. J. Cancer 1992; 52; 873-876.
9. Ropponen K, Tammi M, Parkkinen J et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 1998; 58; 342-347.
10. Kosaki R, Watanabe K, Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res. 1999; 59; 1141-1145.
11. Liu N, Gao F, Han Z, Xu X, Underhill CB, Zhang L. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res. 2001; 61; 5207-5214.
12. Li Y, Heldin P. Hyaluronan production increases the malignant properties of mesothelioma cells. Br. J. Cancer 2001; 85; 600-607.
13. Simpson MA, Wilson CM, Furcht LT, Spicer AP, Oegema TR Jr, McCarthy JB. Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J. Biol. Chem. 2002; 277; 10050-10057.
14. Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol. 2002; 161; 849-857.
15. Nishida Y, Knudson W, Knudson CB, Ishiguro N. Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp. Cell Res. 2005; 307; 194-203.
16. Udabage L, Brownlee GR, Waltham M et al. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res. 2005; 65; 6139-6150.
17. Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp. Cell Res. 2005; 310; 205-217.
18. Li Y, Li L, Brown TJ, Heldin P. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int. J. Cancer 2007; 120; 2557-2567.
19. Bernert B, Porsch H, Heldin P. Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J. Biol. Chem. 2011; 286; 42349-42359.
20. Okuda H, Kobayashi A, Xia B et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res. 2012; 72; 537-547.
21. Ponting J, Kumar S, Pye D. Colocalization of hyaluronan and hyaluronectin in normal and neoplastic breast tissues. Int. J. Oncol. 1993; 2; 889-893.
22. de la Torre M, Wells AF, Bergh J, Lindgren A. Localization of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. Hum. Pathol. 1993; 24; 1294-1297.
23. Auvinen P, Tammi R, Parkkinen J et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 2000; 156; 529-536.
24. Lien HC, Lu YS, Cheng AL et al. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J. Pathol. 2006; 209; 317-327.
25. Lien HC, Hsiao YH, Lin YS et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007; 26; 7859-7871.
26. Heldin P, Basu K, Olofsson B, Porsch H, Kozlova I, Kahata K. Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J. Biochem. 2013; 154; 395-408.
27. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008; 68; 989-997.
28. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol. Oncol. 2010; 4; 192-208.
29. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002; 2; 442-454.
30. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 2009; 119; 1438-1449.
31. Brabletz T, Hlubek F, Spaderna S et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179; 56-65.
32. Camenisch TD, Spicer AP, Brehm-Gibson T et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 2000; 106; 349-360.
33. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat. Med. 2002; 8; 850-855.
34. Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J. Biol. Chem. 2003; 278; 45801-45810.
35. Porsch H, Bernert B, Mehic M, Theocharis AD, Heldin CH, Heldin P. Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 2012; 32; 4355-4365.
36. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008; 216; 141-150.
37. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009; 69; 4116-4124.
38. Deugnier MA, Teuliere J, Faraldo MM, Thiery JP, Glukhova MA. The importance of being a myoepithelial cell. Breast Cancer Res. 2002; 4; 224-230.
39. Moumen M, Chiche A, Cagnet S et al. The mammary myoepithelial cell. Int. J. Dev. Biol. 2011; 55; 763-771.
40. Kendrick H, Regan JL, Magnay FA et al. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 2008; 9; 591.
41. Barsky SH, Karlin NJ. Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell. Nat. Clin. Pract. Oncol. 2006; 3; 138-151.